Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jeffery Lancet
Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients Up to Age Seventy-Five With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Outcomes of Allogeneic Stem Cell Transplant in Patients With Chronic Myelomonocytic Leukemia (CMML) - A Single Institution Experience
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Patients With Acute Erythroleukemia
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Age Does Not Adversely Influence Outcomes Among Patients Older Than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for AML and Myelodysplastic Syndrome
Bone Marrow Transplantation
Transplantation
Hematology
No Association Between Donor Telomere Length and Outcomes After Allogeneic Unrelated Hematopoietic Cell Transplant in Patients With Acute Leukemia
Bone Marrow Transplantation
Transplantation
Hematology
Imatinib Use Either Pre- Or Post-Allogeneic Hematopoietic Cell Transplantation (Allo-Hct) Does Not Increase Cardiac Toxicity in Chronic Myelogenous Leukemia Patients
Bone Marrow Transplantation
Transplantation
Hematology
